Modification of Expanded NK Cells with Chimeric Antigen Receptor mRNA for Adoptive Cellular Therapy
NK cells are bone marrow-derived cytotoxic lymphocytes that play a major role in the rejection of tumors and cells infected by viruses. The regulation of NK activation vs inhibition is regulated by the expression of a variety of NK receptors (NKRs) and specific NKRs’ ligands expressed on their targets. However, factors limiting NK therapy include small numbers of active NK cells in unexpanded peripheral blood and lack of specific tumor targeting. Chimeric antigen receptors (CAR) usually include a single-chain Fv variable fragment from a monoclonal antibody, a transmembrane hinge region, and a signaling domain such as CD28, CD3-zeta, 4-1BB (CD137), or 2B4 (CD244) endodimers. Redirecting NK cells with a CAR will circumvent the limitations of the lack of NK targeting specificity. This chapter focuses on the methods to expand human NK cells from peripheral blood by co-culturing with feeder cells and to modify the expanded NK cells efficiently with the in vitro transcribed CAR mRNA by electroporation and to test the functionality of the CAR-modified expanded NK cells for use in adoptive cellular immunotherapy.
Key wordsChimeric antigen receptor Natural killer cells mRNA Electroporation Adoptive cell therapy
The authors thank Erin Morris, RN, for her excellent assistance with the preparation of this manuscript. The authors also thank Dr. Dario Campana (St. Jude Children’s Research Hospital) and Dr. Terrence Geiger (St. Jude Children’s Research Hospital) for kindly providing anti-CD20 scFv. The research for this study was supported by the grant from the Pediatric Cancer Research Foundation and the New York Medical College Intramural Research Award.
- 11.Eshhar Z, Waks T, Gross G et al (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 90:720–724CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Kochenderfer JN, Dudley ME, Feldman SA et al (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119:2709–2720. doi: 10.1182/blood-2011-10-384388 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Ayello J, van de Ven C, Cairo E et al (2009) Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy. Exp Hematol 37:1216–1229. doi: 10.1016/j.exphem.2009.07.009 CrossRefPubMedGoogle Scholar
- 20.Czuczman MS, Olejniczak S, Gowda A et al (2008) Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 14:1561–1570. doi: 10.1158/1078-0432.CCR-07-1254, 14/5/1561 [pii]CrossRefPubMedGoogle Scholar